Elvitegravir Elvitegravir

Elvitegravir is a drug used for the treatment of HIV infection. It acts as an integrase inhibitor. It was developed by the pharmaceutical company Gilead Sciences, which licensed EVG from Japan Tobacco in March 2008. The drug gained approval by U.S. Food and Drug Administration on August 27, 2012 for use in adult patients starting HIV treatment for the first time as part of the fixed dose combination known as Stribild.
According to the results of the phase II clinical trial, patients taking once-daily elvitegravir boosted by ritonavir had greater reductions in viral load after 24 weeks compared to individuals randomized to receive a ritonavir-boosted protease inhibitor.


Europäische Arzneimittelbehörde: Elvitegravir zur Behandlung von HIV-Infektionen bestätigt

Foster City – Gilead Sciences, Inc. (Nasdaq:GILD) hat heute bekannt gegeben, dass sein Antrag auf die Vermarktung (Marketing Authorisation Application,…

Weiterlesen »
Back to top button